Business Wire

Thales to Deliver the World’s First Fully Integrated Unmanned Mine Countermeasures System for the Royal Navy and French “Marine Nationale”

Share

Following the first phase of the program in which two demonstrators have successfully proven their operational performances at sea, France and the United Kingdom marked the tenth anniversary of the Lancaster House treaties by signing a joint contract for Thales to start the production phase of MMCM to deliver eight unmanned mine hunting systems (four for France and four for the United Kingdom).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201126005783/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

MMCM system at sea ©Thales

With the threat of mines and improvised explosive devices present in all conflicts involving naval forces, countries need to strengthen the protection of their maritime domain, to ensure the protection of their assets and to safeguard the freedom of civil navigation. At the same time, it is essential to limit human exposure to mines. With 50 years of expertise serving navies around the world, Thales develops technologies that enable the transition from conventional solutions, such as minehunters, to unmanned solutions. The MMCM program is the first step in the renewal of the operational concept for mine warfare in France and the United Kingdom, based on the use of unmanned systems which could potentially replace traditional minehunters.

This is a step change in capability, improving performances, productivity and removing the need to place members of the armed forces in harm’s way. It strengthens the leadership of the French Navy and Royal Navy as world leaders in both mine hunting and unmanned systems in the maritime domain.

The subsystems developed for the programme by Thales and its partners include Unmanned Surface Vehicles (USV) to transport and connect solutions and a cutting-edge sonar (SAMDIS) offering unique Single Path Multi View capability to identify and classify threats. The SAMDIS sonar can be carried by Autonomous Underwater Vehicles (AUV) or by Towed Synthetic Aperture Multiviews (TSAM) vehicle operated from the USV. The USV can also carry a Remotely Operated Vehicle (ROV) to neutralize the threats. The entire system is remotely supervised by operators working from a Portable Operational Centre (POC) capable of controlling up to three systems in parallel at sea.

MMCM is the only proven system to offer advanced technologies, including autonomy, to improve performance and productivity thanks to the combination of unrivalled real time user experience using big data exchanges with trusted augmented artificial intelligence (A2I) to provide huge improvement of customer trust in operation clearance and increase the security of national interests. As a result of Thales’s open-architecture approach to MMCM, these new technologies can be easily integrated into the overall system, providing the navies with the opportunity to introduce new operational capabilities, in a planned way, throughout the life of the system.

After the success of the first configuration conducted under real operational conditions with the complete system, Thales is now fully committed to deliver the first operational systems to French and British navies by 2022. This program testifies of the exemplary cooperation between the two states and industrial teams and anchors Thales’s unique expertise and World leading position in conventional MCM, supporting over half the world’s anti-mine vessels with over 300 systems in service.

“Thales is grateful to France and the United Kingdom for trusting such an important technology transition with the Thales teams in France and the UK. To date during trials, the MMCM systems and its assets have covered the equivalent of 30.000 soccer fields at sea, sometimes with very rough sea conditions. This is indeed a step change in how Navies will be able to respond in the future to vicious threats such as mines and improvised explosive devices at sea.” Alexis Morel, VP Underwater Systems, Thales.

About Thales

Thales (Euronext Paris: HO) is a global high technology leader investing in digital and “deep tech” innovations –connectivity, big data, artificial intelligence, cybersecurity and quantum technology – to build a future we can all trust, which is vital to the development of our societies. The company provides solutions, services and products that help its customers –businesses, organisations and states – in the defence, aeronautics, space, transportation and digital identity and security markets to fulfil their critical missions, by placing humans at the heart of the decision-making process.

With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a basis including Gemalto over 12 months).

PLEASE VISIT
Thales Group
Market page
Download HD photos

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS CONTACT
Thales, Media Relations
Land & Naval Defence
Faïza Zaroual
+33 (0)7 81 48 80 41
faiza.zaroual@thalesgroup.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mundipharma and Vectura announce plans to reformulate flutiform ® (fluticasone propionate/formoterol fumarate) pressurised metered-dose inhaler (pMDI) as a commitment to reducing the product’s carbon footprint16.4.2024 11:00:00 CEST | Press release

Mundipharma and Vectura will now progress development of the reformulation of flutiform® (fluticasone propionate/formoterol fumarate) following long-term collaboration, planning and lab-scale development work. The reformulation will ultimately ensure a comparable effective product for patients and further reduce its impact on the environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416962162/en/ The productis an established pressurised metered-dose inhaler (pMDI) for the treatment of asthma, where the use of a combination product is appropriate, and has been available on the market for more than a decade.3 It currently uses the approved apaflurane hydrofluoroalkane 227 (HFA-227), a type of fluorinated greenhouse gas, as its propellant.3 European Union regulation on these types of gases aims to reduce their use, and therefore their emissions, by two-thirds by 2030.1 Work is already under way to source an alternative

Caranx Medical announces successful world first robotic assisted transcatheter heart valve implantation in an animal16.4.2024 10:30:00 CEST | Press release

Caranx Medical (‘Caranx’), a French medical device company specializing in the development of autonomous robot to democratize access to Transcatheter Aortic Valve Implantation (TAVI), a lifesaving procedure, today announced the successful world first robotic assisted heart valve (aortic valve) implantation in an animal. The assisted heart valve implantation in the animal was successfully performed by Dr. Stéphane Lopez, Caranx CMO Dr. Eric Sejor, Caranx CTO Pierre Berthet-Rayne and Caranx team. “This groundbreaking achievement is the result of hard teamwork. At Caranx Medical, we are dedicated to improving patients' lives through true innovation. This successful transcatheter robotic aortic valve implantation marks the first step toward a new generation of intelligent robots guided by AI, set to transform healthcare as we know it” says Pierre Berthet-Rayne, PhD, co-founder and CTO of Caranx. “This major medical first lies not only in the technical achievement of Caranx Medical's engine

Arthur D. Little Publishes Human After All – Latest Edition of PRISM Magazine16.4.2024 10:00:00 CEST | Press release

Arthur D. Little (ADL) has published Human After All – the latest edition of its strategy and innovation magazine PRISM. As we enter the era of AI, the first edition of 2024 highlights the importance of taking a human-centric approach to business management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416226137/en/ Arthur D. Little has published Human After All – the latest edition of its strategy and innovation magazine PRISM. (Graphic: Business Wire) The magazine features seven key articles: Optimistic global CEOs focus on people and skills in an AI future - Our lead article shares highlights from the ADL 2024 CEO Insights Study, finding that CEOs are increasingly confident of future economic success. The people-centric lab of the future – how technology and AI can play a key role in driving breakthrough innovation by enabling people to become perfect innovators. The future workforce - Recruiting and retaining vital

Magnesium Capital closes oversubscribed inaugural Fund at €135m hard cap16.4.2024 09:32:00 CEST | Press release

Magnesium Capital, the Energy Transition buyout specialist, is delighted to announce the successful close of its inaugural Fund, Magnesium Capital I, at its hard cap of €135m, exceeding the €100m Fund target. The final close occurred less than a year after the Fund’s first close with Magnesium attracting blue-clip institutional investors from the US, Europe and the UK. Magnesium focuses on profitable European companies with proven technologies or tech-enabled services that are positively impacting the decarbonisation of the production, distribution and consumption of energy. The team has been backing the buyouts of such businesses for a number of years on a direct deal basis. Since inception, Magnesium has completed seven platform investments, signed six follow-on acquisitions and exited two investments for 4.2x gross MOIC. The combined impact of these portfolio companies already directly contributes to the avoidance of over 30 million tonnes of CO2 equivalent per annum. Ian Jones, Man

MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH00216.4.2024 09:00:00 CEST | Press release

MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today reports positive topline results from its Phase 2a clinical trial with MH002 in the orphan disease indication Pouchitis. MRM Health’s MH002-PC-201 study was a multi-center, open-label clinical trial in 14 acute Pouchitis (PC) patients at multiple clinical sites in Belgium and Italy. The study was designed to evaluate safety (primary objective), initial efficacy, and mechanistic effects of MH002 over 8 weeks. More information about the trial is available at clinicaltrialsregister.eu. The trial met its primary objective with an excellent safety and tolerability at a fixed dose of 400mg per day over 8 weeks’ administration. Treatment-Emergent Adverse Events (TEAE) reported were predominantly mild and unrelated, and there was no evidence of adverse reactions related to MH002. It also demonstrated initial efficacy in clinically relevant parameters,

HiddenA line styled icon from Orion Icon Library.Eye